using compounded semaglutide after 28 days FDA Warns on Certain Forms of altRx GLP-1 Review 2026: Updated
Description
When combined, these variables affect the effective, or serviceable, addressable market for GLP-1 drugs
Documented Heart Rate Increases : As noted in FDA prescribing information, semaglutide can increase resting heart rate by an average of 1-4 beats per minute, with some patients experiencing greater increases
doi:10.1002/dmrr.1080 73
For convenience, well use GLP-1 as the broad term throughout this article
